Immutep Ltd: Evaluating the Safety and Efficacy of Eftilagimod Alpha in Combination with Merck’s KEYTRUDA

Immutep Ltd and Merck Announce Second Clinical Trial Collaboration

Immutep (IMMP) develops novel immunotherapy treatments for cancer, infectious disease and autoimmune diseases.

Today, Immutep announced a second clinical trial collaboration and supply agreement with Merck & Co (MRK) subsidiaries, Kenilworth, NJ, USA (known as “MSD” outside the United States and Canada).

Immutep will conduct a new Phase IIb clinical trial in 1st line head and neck squamous cell carcinoma (HNSCC) patients.

The trial, called TACTI-003 (Two Active Immunotherapies), will be a 1:1 randomized, controlled clinical study in approximately 160 first-line HNSCC patients.

The trial will evaluate the safety and efficacy of Immutep’s lead product candidate, eftilagimod alpha (efti or IMP321) in combination with Merck’s immunotherapy product KEYTRUDA® (pembrolizumab), compared to pembrolizumab alone.

Leave a Reply